Fig. 7

Western blotting. The antibodies against Bcl-2 (a1), HO-1 (a1), P-p38 (c1), MMP-9 (d1) and β-actin are respectively shown as 26, 34.6, 43, 92~96 and 43-kDa bands. Each bar represents the ratio of Bcl-2 (n = 4–9; a2), HO-1 (n = 4; b2), P-p38 (n = 4-9; c2), or MMP-9 (n = 4–5; d2) to β-actin. * or ^†represents significance (P < 0.05; Group 1 vs. 2) or significance (P < 0.05; Group 2 vs. 4, I/R + CJDHW4.2; Group 2 vs. 5, SB203580), respectively. Additionally, for P-p38, ** or ^††/†represents significance (P < 0.01; Group 1 vs. 2) or significance (P < 0.01/P < 0.05; Group 2 vs. 5/Group 2 vs. 4), respectively. These 5 Groups included Group 1 as well as Groups 2, 3, 4 and 5 [(the retina subjected to ischemia plus reperfusion respectively pretreated with vehicle (I/R + Vehicle), 2.8 g/kg/day of CJDHW (I/R + CJDHW2.8), 4.2 g/kg/day of CJDHW (I/R + CJDHW4.2) and SB203580 (p38 MAPK inhibitor)]. The results are presented as the mean ± SD